Advanced search
Publication Cover
Drug Delivery Volume 25, 2018 - Issue 1
Submit an article Journal homepage
116,370
Views
650
CrossRef citations to date
0
Altmetric
Review Article

Delivering CRISPR: a review of the challenges and approaches

Christopher A. LinoBioenergy and Defense Technologies, Sandia National Laboratories, Albuquerque, NM, USAView further author information
,
Jason C. HarperBioenergy and Defense Technologies, Sandia National Laboratories, Albuquerque, NM, USAView further author information
,
James P. CarneyBioenergy and Defense Technologies, Sandia National Laboratories, Albuquerque, NM, USAView further author information
&
Jerilyn A. TimlinBioenergy and Defense Technologies, Sandia National Laboratories, Albuquerque, NM, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2953-1721View further author information
ORCID Icon
Pages 1234-1257 | Received 12 Feb 2018, Accepted 07 May 2018, Published online: 25 May 2018

References

  • Ahi YS, Bangari DS, Mittal SK. (2011). Adenoviral vector immunity: its implications and circumvention strategies. CGT 11:307–20.
  • Anders C, Bargsten K, Jinek M. (2016). Structural plasticity of PAM recognition by engineered variants of the RNA-guided endonuclease Cas9. Mol Cell 61:895–902.
  • Anders C, Niewoehner O, Duerst A, Jinek M. (2014). Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513:569–73.
  • Axford DS, Morris DP, McMurry JL. (2017). Cell penetrating peptide-mediated nuclear delivery of Cas9 to enhance the utility of CRISPR/Cas genome editing. FASEB J 31:909.4.
  • Barrangou R, Fremaux C, Deveau H, et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:1709–12.
  • Bates K, Kostarelos K. (2013). Carbon nanotubes as vectors for gene therapy: past achievements, present challenges and future goals. Adv Drug Deliv Rev 65:2023–33.
  • Bestor TH. (2000). Gene silencing as a threat to the success of gene therapy. J Clin Invest 105:409–11.
  • Bibikova M, Beumer K, Trautman JK, Carroll D. (2003). Enhancing gene targeting with designed zinc finger nucleases. Science 300:764.
  • Bibikova M, Golic M, Golic K, Carroll GD. (2002). Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161:1169–75.
  • Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. (2005). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151:2551–61.
  • Bolukbasi MF, Gupta A, Oikemus S, et al. (2015). DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat Methods 12:1150–6.
  • Bonamassa B, Hai L, Liu D. (2011). Hydrodynamic gene delivery and its applications in pharmaceutical research. Pharm Res 28:694–701.
  • Brito JL, Davies FE, Gonzalez D, Morgan GJ. (2008). Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J Immunol Methods 333:147–55.
  • Brouns SJ, Jore MM, Lundgren M, et al. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321:960–4.
  • Capecchi MR. (1989). Altering the genome by homologous recombination. Science 244:1288–92.
  • Carroll D. (2011). Genome engineering with zinc-finger nucleases. Genetics 188:773–82.
  • Carroll KJ, Makarewich CA, McAnally J, et al. (2016). A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci USA 113:338–43.
  • Cavazzana M, Six E, Lagresle-Peyrou C, et al. (2016). Gene therapy for X-linked severe combined immunodeficiency: where do we stand? Hum Gene Ther 27:108–16.
  • Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–72.
  • Cermak T, Doyle EL, Christian M, et al. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39:e82.
  • Check E. (2002). A tragic setback. Nature 420:116–8.
  • Chen X, Goncalves MA. (2016). Engineered viruses as genome editing devices. Mol Ther 24:447–57.
  • Cheng R, Peng J, Yan Y, et al. (2014). Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett 588:3954–8.
  • Chen S, Lee B, Lee AY, et al. (2016). Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes. J Biol Chem 291:14457–67.
  • Chen F, Pruett-Miller SM, Huang Y, et al. (2011). High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 8:753–5.
  • Chew WL, Tabebordbar M, Cheng JK, et al. (2016). A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13:868–74.
  • Choi PS, Meyerson M. (2014). Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun 5:3728.
  • Cho SW, Kim S, Kim Y, et al. (2014). Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132–41.
  • Cho SW, Kim S, Kim JM, Kim JS. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31:230–2.
  • Christian M, Cermak T, Doyle EL, et al. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757–61.
  • Chu VT, Weber T, Wefers B, et al. (2015). Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 33:543–8.
  • Chuang CK, Chen CH, Huang CL, et al. (2017). Generation of GGTA1 mutant pigs by direct pronuclear microinjection of CRISPR/Cas9 plasmid vectors. Anim Biotechnol 28:174–81.
  • Chylinski K, Le Rhun A, Charpentier E. (2013). The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 10:726–37.
  • Chylinski K, Makarova KS, Charpentier E, Koonin EV. (2014). Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res 42:6091–105.
  • Cong L, Ran FA, Cox D, et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–23.
  • Cox DB, Platt RJ, Zhang F. (2015). Therapeutic genome editing: prospects and challenges. Nat Med 21:121–31.
  • Cradick TJ, Fine EJ, Antico CJ, Bao G. (2013). CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41:9584–92.
  • Crispo M, Mulet AP, Tesson L, et al. (2015). Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes. PLoS One 10:e0136690.
  • D'Astolfo DS, Pagliero RJ, Pras A, et al. (2015). Efficient intracellular delivery of native proteins. Cell 161:674–690.
  • Daya S, Berns KI. (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583–93.
  • Deltcheva E, Chylinski K, Sharma CM, et al. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471:602–7.
  • Deng W, Shi X, Tjian R, et al. (2015). CASFISH: CRISPR/Cas9-mediated in situ labeling of genomic loci in fixed cells. Proc Natl Acad Sci USA 112:11870–5.
  • Deyle DR, Russell DW. (2009). Adeno-associated virus vector integration. Curr Opin Mol Ther 11:442–7.
  • Ding Q, Strong A, Patel KM, et al. (2014). Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115:488–92.
  • Doench JG, Hartenian E, Graham DB, et al. (2014). Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32:1262–7.
  • Dong C, Qu L, Wang H, et al. (2015). Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118:110–7.
  • Dow LE, Fisher J, O'Rourke KP, et al. (2015). Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33:390–4.
  • Doyon Y, Vo TD, Mendel MC, et al. (2011). Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 8:74–9.
  • Du X, Shi B, Tang Y, et al. (2014). Label-free dendrimer-like silica nanohybrids for traceable and controlled gene delivery. Biomaterials 35:5580–90.
  • Durfee PN, Lin YS, Dunphy DR, et al. (2016). Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells. ACS Nano 10:8325–45.
  • Dykman LA, Khlebtsov NG. (2017). Immunological properties of gold nanoparticles. Chem Sci 8:1719–35.
  • Ebina H, Misawa N, Kanemura Y, Koyanagi Y. (2013). Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3:2510.
  • Esvelt KM, Mali P, Braff JL, et al. (2013). Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10:1116–21.
  • Findlay GM, Boyle EA, Hause RJ, et al. (2014). Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513:120–3.
  • Follenzi A, Santambrogio L, Annoni A. (2007). Immune responses to lentiviral vectors. Curr Gene Ther 7:306–15.
  • Fu Y, Foden JA, Khayter C, et al. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31:822–6.
  • Gabriel R, Lombardo A, Arens A, et al. (2011). An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29:816–23.
  • Garrett RA, Shah SA, Erdmann S, et al. (2015). CRISPR-Cas adaptive immune systems of the sulfolobales: unravelling their complexity and diversity. Life (Basel, Switzerland) 5:783–817.
  • Gaspar HB, Cooray S, Gilmour KC, et al. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Translational Med 3:97ra79.
  • Gaspar HB, Parsley KL, Howe S, et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (London, England) 364:2181–7.
  • Gaudelli NM, Komor AC, Rees HA, et al. (2017). Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551:464–71.
  • Gilbert LA, Horlbeck MA, Adamson B, et al. (2014). Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159:647–61.
  • Gonzalez Porras MA, Durfee PN, Gregory AM, et al. (2016). A novel approach for targeted delivery to motoneurons using cholera toxin-B modified protocells. J Neurosci Methods 273:160–74.
  • Guan Y, Ma Y, Li Q, et al. (2016). CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med 8:477–88.
  • Guilinger JP, Thompson DB, Liu DR. (2014). Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32:577–82.
  • Gupta RM, Musunuru K. (2014). Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest 124:4154–61.
  • Hacein-Bey-Abina S, Hauer J, Lim A, et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363:355–64.
  • Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185–93.
  • Haeussler M, Schonig K, Eckert H, et al. (2016). Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol 17:148.
  • Hashimoto M, Takemoto T. (2015). Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. Sci Rep 5:11315.
  • Heckl D, Kowalczyk MS, Yudovich D, et al. (2014). Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941–6.
  • Hefferin ML, Tomkinson AE. (2005). Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst) 4:639–48.
  • Hilton IB, D'Ippolito AM, Vockley CM, et al. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33:510–7.
  • Hirano S, Nishimasu H, Ishitani R, Nureki O. (2016). Structural basis for the altered PAM specificities of engineered CRISPR-Cas9. Mol Cell 61:886–94.
  • Horii T, Arai Y, Yamazaki M, et al. (2014). Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering. Sci Rep 4:4513.
  • Horii T, Tamura D, Morita S, et al. (2013). Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. IJMS 14:19774–81.
  • Hou Z, Zhang Y, Propson NE, et al. (2013). Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci 110:15644–9.
  • Hsu PD, Scott DA, Weinstein JA, et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31:827–32.
  • Hung SS, Chrysostomou V, Li F, et al. (2016). AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo. Invest Ophthalmol Vis Sci 57:3470–6.
  • Ishino Y, Shinagawa H, Makino K, et al. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169:5429–33.
  • Jansen R, Embden JD, Gaastra W, Schouls LM. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43:1565–75.
  • Jiang W, Bikard D, Cox D, et al. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31:233–9.
  • Jinek M, Chylinski K, Fonfara I, et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–21.
  • Jinek M, Jiang F, Taylor DW, et al. (2014). Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343:1247997.
  • Joung JK, Sander JD. (2013). TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14:49–55.
  • Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. (2014). Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res 42:e147.
  • Kaiser J. (2003). Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 299:495.
  • Kennedy EM, Kornepati AV, Goldstein M, et al. (2014). Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol 88:11965–72.
  • Kim S, Kim D, Cho SW, et al. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24:1012–9.
  • Kleinstiver BP, Pattanayak V, Prew MS, et al. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–5.
  • Kleinstiver BP, Prew MS, Tsai SQ, et al. (2015). Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol 33:1293–8.
  • Kleinstiver BP, Prew MS, Tsai SQ, et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481–5.
  • Kogure K, Moriguchi R, Sasaki K, et al. (2004). Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 98:317–23.
  • Koike-Yusa H, Li Y, Tan EP, et al. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32:267–73.
  • Konermann S, Brigham MD, Trevino AE, et al. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–8.
  • LaFountaine JS, Fathe K, Smyth HD. (2015). Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm 494:180–94.
  • Lander ES. (2016). The heroes of CRISPR. Cell 164:18–28.
  • Ledford H. (2016). CRISPR: gene editing is just the beginning. Nature 531:156–9.
  • Lee K, Conboy M, Park HM, et al. (2017). Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 1:889–901.
  • Liang X, Potter J, Kumar S, et al. (2015). Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 208:44–53.
  • Li C, Guan X, Du T, et al. (2015). Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol 96:2381–93.
  • Li T, Huang S, Jiang WZ, et al. (2011). TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 39:359–72.
  • Lin S, Staahl BT, Alla RK, Doudna JA. (2014). Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 3:e04766.
  • Lin SR, Yang HC, Kuo YT, et al. (2014). The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 3:e186.
  • Liu J, Stace-Naughton A, Jiang X, Brinker CJ. (2009). Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc 131:1354–5.
  • Liu Y, Zeng Y, Liu L, et al. (2014). Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat Commun 5:5393.
  • Long C, Amoasii L, Mireault AA, et al. (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400–3.
  • Long C, McAnally JR, Shelton JM, et al. (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345:1184–8.
  • Luo GF, Chen WH, Liu Y, et al. (2014). Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide. Sci Rep 4:6064.
  • Luo D, Saltzman WM. (2000). Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol 18:893–5.
  • Mackowiak SA, Schmidt A, Weiss V, et al. (2013). Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano Lett 13:2576–83.
  • Ma H, Dang Y, Wu Y, et al. (2015). A CRISPR-based screen identifies genes essential for West-Nile-Virus-induced cell death. Cell Rep 12:673–83.
  • Maddalo D, Manchado E, Concepcion CP, et al. (2014). In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516:423–7.
  • Maggio I, Stefanucci L, Janssen JM, et al. (2016). Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Res 44:1449–70.
  • Makarova KS, Haft DH, Barrangou R, et al. (2011). Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9:467–77.
  • Makarova KS, Koonin EV. (2015). Annotation and classification of CRISPR-Cas systems. Methods Mol Biol 1311:47–75.
  • Makarova KS, Wolf YI, Alkhnbashi OS, et al. (2015). An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13:722–36.
  • Mali P, Aach J, Stranges PB, et al. (2013). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31:833–8.
  • Mali P, Yang L, Esvelt KM, et al. (2013). RNA-guided human genome engineering via Cas9. Science 339:823–6.
  • Ma H, Naseri A, Reyes-Gutierrez P, et al. (2015). Multicolor CRISPR labeling of chromosomal loci in human cells. Proc Natl Acad Sci USA 112:3002–7.
  • Marshall E. (1999). Gene therapy death prompts review of adenovirus vector. Science 286:2244–5.
  • Maruyama T, Dougan SK, Truttmann MC, et al. (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33:538–42.
  • Ma Y, Shen B, Zhang X, et al. (2014). Heritable multiplex genetic engineering in rats using CRISPR/Cas9. PLoS One 9:e89413.
  • Matano M, Date S, Shimokawa M, et al. (2015). Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 21:256–62.
  • Ma Y, Zhang L, Huang X. (2014). Genome modification by CRISPR/Cas9. FEBS J 281:5186–93.
  • Miller JC, Holmes MC, Wang J, et al. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25:778–85.
  • Miller JC, Tan S, Qiao G, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29:143–8.
  • Miller JB, Zhang S, Kos P, et al. (2017). Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl 56:1059–63.
  • Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60:174–82.
  • Mojica FJ, Diez-Villasenor C, Soria E, Juez G. (2000). Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol 36:244–6.
  • Mojica FJ, Juez G, Rodriguez-Valera F. (1993). Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Mol Microbiol 9:613–21.
  • Moreno-Mateos MA, Vejnar CE, Beaudoin JD, et al. (2015). CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat Methods 12:982–8.
  • Mout R, Ray M, Yesilbag Tonga G, et al. (2017). Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. ACS Nano 11:2452–8.
  • Mussolino C, Alzubi J, Fine EJ, et al. (2014). TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res 42:6762–73.
  • Nakagawa Y, Sakuma T, Sakamoto T, et al. (2015). Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-thawed fertilized oocytes. BMC Biotechnol 15:33.
  • Nakamura T, Akita H, Yamada Y, et al. (2012). A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc Chem Res 45:1113–21.
  • Naldini L, Blomer U, Gallay P, et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–7.
  • Nelson CE, Hakim CH, Ousterout DG, et al. (2016). In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403–7.
  • Nihongaki Y, Kawano F, Nakajima T, Sato M. (2015). Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol 33:755–60.
  • NIH Report. (2002). Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 13:3–13.
  • Nishimasu H, Cong L, Yan WX, et al. (2015). Crystal structure of Staphylococcus aureus Cas9. Cell 162:1113–26.
  • Niu Y, Shen B, Cui Y, et al. (2014). Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836–43.
  • Ousterout DG, Kabadi AM, Thakore PI, et al. (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6:6244.
  • Papapetrou EP, Schambach A. (2016). Gene insertion into genomic safe harbors for human gene therapy. Mol Ther 24:678–84.
  • Paquet D, Kwart D, Chen A, et al. (2016). Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533:125–9.
  • Pattanayak V, Lin S, Guilinger JP, et al. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31:839–43.
  • Pattanayak V, Ramirez CL, Joung JK, Liu DR. (2011). Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8:765–70.
  • Platt RJ, Chen S, Zhou Y, et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–55.
  • Polstein LR, Gersbach CA. (2015). A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol 11:198–200.
  • Pourcel C, Salvignol G, Vergnaud G. (2005). CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151:653–63.
  • Qi LS, Larson MH, Gilbert LA, et al. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–83.
  • Qin W, Dion SL, Kutny PM, et al. (2015). Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics 200:423–30.
  • Radecke S, Radecke F, Cathomen T, Schwarz K. (2010). Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. Mol Ther 18:743–53.
  • Raitskin O, Patron NJ. (2016). Multi-gene engineering in plants with RNA-guided Cas9 nuclease. Curr Opin Biotechnol 37:69–75.
  • Ramakrishna S, Kwaku Dad AB, Beloor J, et al. (2014). Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 24:1020–7.
  • Ramirez CL, Foley JE, Wright DA, et al. (2008). Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods 5:374–5.
  • Ran FA, Cong L, Yan WX, et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186–91.
  • Ran FA, Hsu PD, Lin CY, et al. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380–9.
  • Raveux A, Vandormael-Pournin S, Cohen-Tannoudji M. (2017). Optimization of the production of knock-in alleles by CRISPR/Cas9 microinjection into the mouse zygote. Sci Rep 7:42661.
  • Reyon D, Tsai SQ, Khayter C, et al. (2012). FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30:460–5.
  • Robert F, Barbeau M, Ethier S, et al. (2015). Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med 7:93.
  • Roehm PC, Shekarabi M, Wollebo HS, et al. (2016). Inhibition of HSV-1 replication by gene editing strategy. Sci Rep 6:23146.
  • Ross J. (1995). mRNA stability in mammalian cells. Microbiol Rev 59:423–50.
  • Rouet P, Smih F, Jasin M. (1994). Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci USA 91:6064–8.
  • Sakuma T, Nishikawa A, Kume S, et al. (2014). Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci Rep 4:5400.
  • Samulski RJ, Muzyczka N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1:427–51.
  • Sato M, Koriyama M, Watanabe S, et al. (2015). Direct injection of CRISPR/Cas9-related mRNA into cytoplasm of parthenogenetically activated porcine oocytes causes frequent mosaicism for indel mutations. Ijms 16:17838–56.
  • Schumann K, Lin S, Boyer E, et al. (2015). Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 112:10437–42.
  • Schwank G, Koo BK, Sasselli V, et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13:653–8.
  • Shalem O, Sanjana NE, Hartenian E, et al. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84–7.
  • Shen B, Zhang J, Wu H, et al. (2013). Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23:720–3.
  • Shmakov S, Abudayyeh OO, Makarova KS, et al. (2015). Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell 60:385–97.
  • Sierig G, Cywes C, Wessels MR, Ashbaugh CD. (2003). Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect Immun 71:446–55.
  • Slaymaker IM, Gao L, Zetsche B, et al. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–8.
  • Soldner F, Laganiere J, Cheng AW, et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146:318–31.
  • Srivastava M, Nambiar M, Sharma S, et al. (2012). An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151:1474–87.
  • Sternberg SH, Redding S, Jinek M, et al. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507:62–7.
  • Strutt SC, Torrez RM, Kaya E, et al. (2018). RNA-dependent RNA targeting by CRISPR-Cas9. Elife 7.
  • Su J, Sun H, Meng Q, et al. (2017). Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics 7:523–37.
  • Suda T, Gao X, Stolz DB, Liu D. (2007). Structural impact of hydrodynamic injection on mouse liver. Gene Ther 14:129–37.
  • Sun W, Jiang T, Lu Y, et al. (2014). Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J Am Chem Soc 136:14722–5.
  • Sun W, Ji W, Hall JM, et al. (2015). Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl 54:12029–33.
  • Swiech L, Heidenreich M, Banerjee A, et al. (2015). In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–6.
  • Szczelkun MD, Tikhomirova MS, Sinkunas T, et al. (2014). Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. Proc Natl Acad Sci USA 111:9798–803.
  • Tabebordbar M, Zhu K, Cheng JKW, et al. (2016). In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351:407–11.
  • Takata M, Sasaki MS, Sonoda E, et al. (1998). Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17:5497–508.
  • Tanenbaum ME, Gilbert LA, Qi LS, et al. (2014). A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159:635–46.
  • Teng KW, Ishitsuka Y, Ren P, et al. (2017). Labeling proteins inside living cells using external fluorophores for fluorescence microscopy. Elife 6:e25460.
  • Thomas CE, Ehrhardt A, Kay MA. (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346–58.
  • Tomkinson AE, Howes TR, Wiest NE. (2013). DNA ligases as therapeutic targets. Translational Cancer Res 2:1219.
  • Truong DJ, Kuhner K, Kuhn R, et al. (2015). Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res 43:6450–8.
  • Tsai SQ, Wyvekens N, Khayter C, et al. (2014). Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32:569–76.
  • Urnov FD, Rebar EJ, Holmes MC, et al. (2010). Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636–46.
  • van der Oost J, Jore MM, Westra ER, et al. (2009). CRISPR-based adaptive and heritable immunity in prokaryotes. Trends Biochem Sci 34:401–7.
  • van Soolingen D, de Haas PE, Hermans PW, et al. (1993). Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol 31:1987–95.
  • Vartak SV, Raghavan SC. (2015). Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing. FEBS J 282:4289–94.
  • Voets O, Tielen F, Elstak E, et al. (2017). Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells. PLoS One 12:e0182974.
  • Vora S, Tuttle M, Cheng J, Church G. (2016). Next stop for the CRISPR revolution: RNA-guided epigenetic regulators. FEBS J 283:3181–93.
  • Walev I, Bhakdi SC, Hofmann F, et al. (2001). Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A 98:3185–90.
  • Wang D, Huang J, Wang X, et al. (2013). The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 34:7662–73.
  • Wang D, Mou H, Li S, et al. (2015). Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 26:432–42.
  • Wang J, Quake SR. (2014). RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci 111:13157–62.
  • Wang T, Wei JJ, Sabatini DM, Lander ES. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80–4.
  • Wang H, Yang H, Shivalila CS, et al. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153:910–8.
  • Wang M, Zuris JA, Meng F, et al. (2016). Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci USA 113:2868–73.
  • Weinstock DM, Jasin M. (2006). Alternative pathways for the repair of RAG-induced DNA breaks. Mol Cell Biol 26:131–9.
  • Wiedenheft B, Lander GC, Zhou K, et al. (2011). Structures of the RNA-guided surveillance complex from a bacterial immune system. Nature 477:486–9.
  • Wolfe SA, Nekludova L, Pabo CO. (2000). DNA recognition by Cys2His2 zinc finger proteins. Annu Rev Biophys Biomol Struct 29:183–212.
  • Wright AV, Nunez JK, Doudna JA. (2016). Biology and applications of CRISPR systems: Harnessing Nature's Toolbox for genome engineering. Cell 164:29–44.
  • Wu Y, Liang D, Wang Y, et al. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13:659–62.
  • Wu Z, Yang H, Colosi P. (2010). Effect of genome size on AAV vector packaging. Mol Ther 18:80–6.
  • Wu Y, Zhou H, Fan X, et al. (2015). Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res 25:67–79.
  • Xu H, Xiao T, Chen CH, et al. (2015). Sequence determinants of improved CRISPR sgRNA design. Genome Res 25:1147–57.
  • Xue W, Chen S, Yin H, et al. (2014). CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514:380–4.
  • Yang H, Wang H, Shivalila CS, et al. (2013). One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154:1370–9.
  • Yao S, He Z, Chen C. (2015). CRISPR/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Hum Gene Ther 26:463–71.
  • Ye L, Wang J, Beyer AI, et al. (2014). Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111:9591–6.
  • Yin H, Song CQ, Dorkin JR, et al. (2016). Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34:328–33.
  • Yin H, Xue W, Chen S, et al. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32:551–3.
  • Yu C, Liu Y, Ma T, et al. (2015). Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16:142–7.
  • Zhang D, Li Z, Li JF. (2016). Targeted gene manipulation in plants using the CRISPR/Cas technology. J Genet Genomics = Yi Chuan Xue Bao 43:251–62.
  • Zhang R, Miner JJ, Gorman MJ, et al. (2016). A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 535:164–8.
  • Zhang Y, Ma X, Xie X, Liu Y-G. (2017). CRISPR/Cas9-based genome editing in plants. Prog Mol Biol Transl Sci 149:133–50.
  • Zhang Z, Zhang S, Huang X, et al. (2013). Rapid assembly of customized TALENs into multiple delivery systems. PLoS One 8:e80281.
  • Zhen S, Hua L, Liu YH, et al. (2015). Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther 22:404–12.
  • Zhou Y, Zhu S, Cai C, et al. (2014). High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509:487–91.
  • Zhu H, Lau CH, Goh SL, et al. (2013). Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res 41:e180.
  • Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, et al. (2015). Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun 6:7391.
  • Zuris JA, Thompson DB, Shu Y, et al. (2015). Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:73–80.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.